Division of Nephrology, Department of Medicine, Stanford University School of Medicine, 1070 Arastradero Rd,, Suite 313, Palo Alto, CA 94304, USA.
BMC Nephrol. 2013 Apr 26;14:97. doi: 10.1186/1471-2369-14-97.
Impaired kidney function is an established predictor of mortality after acute nonvariceal upper gastrointestinal bleeding (ANVUGIB); however, which factors are associated with mortality after ANVUGIB among patients undergoing dialysis is unknown. We examined the associations among demographic characteristics, dialysis-specific features, and comorbid conditions with short-term mortality after ANVUGIB among patients on dialysis.
Retrospective cohort study.
United States Renal Data System (USRDS), a nation-wide registry of patients with end-stage renal disease.
All ANVUGIB episodes identified by validated algorithms in Medicare-covered patients between 2003 and 2007.
Demographic characteristics and comorbid conditions from 1 year of billing claims prior to each bleeding event. We used logistic regression extended with generalized estimating equations methods to model the associations among risk factors and 30-day mortality following ANVUGIB events.
From 2003 to 2007, we identified 40,016 eligible patients with 50,497 episodes of ANVUGIB. Overall 30-day mortality was 10.7% (95% CI: 10.4-11.0). Older age, white race, longer dialysis vintage, peritoneal dialysis (vs. hemodialysis), and hospitalized (vs. outpatient) episodes were independently associated with a higher risk of 30-day mortality. Most but not all comorbid conditions were associated with death after ANVUGIB. The joint ability of all factors captured to discriminate mortality was modest (c=0.68).
We identified a profile of risk factors for 30-day mortality after ANVUGIB among patients on dialysis that was distinct from what had been reported in non-dialysis populations. Specifically, peritoneal dialysis and more years since initiation of dialysis were independently associated with short-term death after ANVUGIB.
肾功能受损是急性非静脉曲张性上消化道出血(ANVUGIB)后死亡的既定预测因素;然而,在接受透析的患者中,哪些因素与 ANVUGIB 后的死亡率相关尚不清楚。我们研究了透析患者中 ANVUGIB 后短期死亡率与人口统计学特征、透析特异性特征和合并症之间的相关性。
回顾性队列研究。
美国肾脏数据系统(USRDS),这是一个全国性的终末期肾脏疾病患者登记处。
在 2003 年至 2007 年期间,通过医疗保险覆盖患者的验证算法确定的所有 ANVUGIB 发作。
出血事件前一年的计费索赔中的人口统计学特征和合并症。我们使用逻辑回归扩展广义估计方程方法,对 ANVUGIB 事件后 30 天死亡率与危险因素之间的关系进行建模。
在 2003 年至 2007 年期间,我们确定了 40016 名符合条件的患者,其中 50497 例 ANVUGIB 发作。总体 30 天死亡率为 10.7%(95%CI:10.4-11.0)。年龄较大、白人、透析时间较长、腹膜透析(vs. 血液透析)和住院(vs. 门诊)发作与 30 天死亡率升高独立相关。大多数但不是所有合并症都与 ANVUGIB 后的死亡相关。所有因素联合识别死亡率的能力中等(c=0.68)。
我们确定了透析患者 ANVUGIB 后 30 天死亡率的危险因素特征,与非透析人群中的报告不同。具体而言,腹膜透析和开始透析后更长时间与 ANVUGIB 后短期死亡独立相关。